Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients

Intensive Care Medicine

Volumn 38, Issue 1, 2012, Pages 76-84

  Kirwan, C J ^b   MacPhee, I A M ^a   Lee, T ^a   Holt, D W ^a   Philips, B J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute kidney injury; Critical illness; Cytochrome P450; Hepatic metabolism; Midazolam; Pharmacogenetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; CYSTATIN C; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; GAMMA GLUTAMYLTRANSFERASE; MIDAZOLAM; UREA; CYP3A5 PROTEIN, HUMAN; INTRAVENOUS ANESTHETIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; PH; PREDICTIVE VALUE; PROTEIN EXPRESSION; RESUSCITATION; UREA BLOOD LEVEL; URINE VOLUME; BLOOD; CRITICAL ILLNESS; GENETICS; HOSPITALIZATION; LIVER; METABOLISM; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; ANESTHETICS, INTRAVENOUS; CRITICAL ILLNESS; CYTOCHROME P-450 CYP3A; GENOTYPE; HUMANS; LIVER; MIDAZOLAM; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84859927163     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-011-2360-8     Document Type: Article

References (40)

1. James MT, Wald R, Bell CM, Tonelli M, Hemmelgarn BR, Waikar SS, Chertow GM (2010) Weekend hospital admission, acute kidney injury, and mortality. J Am Soc Nephrol 21:845-851
2. Kolhe NV, Stevens PE, Crowe AV, Lipkin GW, Harrison DA (2008) Case mix, outcome and activity for patients with severe acute kidney injury during the first 24 hours after admission to an adult, general critical care unit: application of predictive models from a secondary analysis of the ICNARC Case Mix Programme database. Crit Care 12(Suppl 1):S2
3. Tian J, Barrantes F, Amoateng-Adjepong Y, Manthous CA (2009) Rapid reversal of acute kidney injury and hospital outcomes: a retrospective cohort study. Am J Kidney Dis 53:974-981
4. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212
5. Joannidis M, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W, Metnitz PG (2009) Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med 35:1692-1702
6. Kociol R, Rogers J, Shaw A (2009) Organ cross talk in the critically ill: the heart and kidney. Blood Purif 27:311-320
7. Ricci Z, Ronco C (2010) Pulmonary/renal interaction. Curr Opin Crit Care 16:13-18
8. Hoste EA, De Waele JJ (2005) Physiologic consequences of acute renal failure on the critically ill. Crit Care Clin 21:251-260
9. Ronco C (2010) Cardiorenal syndromes: definition and classification. Contrib Nephrol 164:33-38
10. Kirwan CJ, Lee T, Holt DW, Grounds RM, MacPhee IA, Philips BJ (2009) Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 35:1271-1275
11. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL (2003) Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73:427-434
12. Dreisbach AW, Lertora JJ (2003) The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 16:45-50
13. Michaud J, Dube P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V (2005) Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 144:1067-1077
14. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V (2002) Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137:1039-1046
15. Finta C, Zaphiropoulos PG (2000) The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13-23
16. Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, Konings F, Armstrong M (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415-424
17. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA (2001) The role of hepatic and extrahepatic UDPglucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297
18. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562
19. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 66:288-294
20. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr., Bhat K, Kim RB, Wilkinson GR (2003) Genotypephenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-And African-American men and women. Pharmacogenetics 13:595-606
21. Fredericks S, Moreton M, MacPhee IA, Mohamed M, Marlowe S, Jorga A, Johnston A, Carter ND, Holt DW (2005) Genotyping cytochrome P450 using the Light Cycler. Ann Clin Biochem 42:376-381
22. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098
23. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther 68:82-91
24. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS (2008) The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74:101-107
25. Driessen JJ, Vree TB, Guelen PJ (1991) The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 42:149-155
26. Rogers JF, Rocci ML Jr., Haughey DB, Bertino JS Jr. (2003) An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 73:153-158
27. Fragen RJ (1997) Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. Clin Ther 19:405-419 (discussion 367-408)
28. Wiedermann CJ, Wiedermann W, Joannidis M (2010) Hypoalbuminemia and acute kidney injury: a meta-Analysis of observational clinical studies. Intensive Care Med 36:1657-1665
29. Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F (2010) Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-Analysis. Int J Obes (Lond) 34:791-799
30. Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L (2006) Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 55:515-524
31. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW (2004) The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 4:914-919
32. Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM (2009) 'Liver function tests' on the intensive care unit: a prospective, observational study. Intensive Care Med 35:1406-1411
33. Chow PKH, Yu W-K, Soo K-C, Chan STF (2003) The measurement of liver blood flow: a review of experimental and clinical methods. J Surg Res 112:1-11
34. Swart EL, van der Hoven B, Groeneveld AB, Touw DJ, Danhof M (2002) Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol 53:133-139
35. Mizushima Y, Tohira H, Mizobata Y, Matsuoka T, Yokota J (2003) Assessment of effective hepatic blood flow in critically ill patients by noninvasive pulse dye-densitometry. Surg Today 33:101-105
36. Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J (2009) ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 20:2269-2276
37. Brandi LSMD, Bertolini RMD, Santini LMD, Cavani SMD (1999) Effects of ventilator resetting on indirect calorimetry measurement in the critically ill surgical patient. Crit Care Med 27:531-539
38. Kurnik D, Wood AJJ, Wilkinson GR (2006) The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80:228-234
39. Chaobal HN, Kharasch ED (2005) Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 78:529-539
40. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y (2008) Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 18:861-868